Royalty Pharma
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $578,665 | $568,247 | $593,641 | $564,690 |
Gross Profit | 578,665 | 568,247 | 593,641 | 564,690 |
EBITDA | 159,303 | 498,694 | 400,112 | 872,864 |
EBIT | 209,799 | 534,182 | 361,514 | 735,074 |
Net Income | 30,176 | 238,349 | 208,214 | 543,987 |
Net Change In Cash | 578,665 | 568,247 | 593,641 | 564,690 |
Free Cash Flow | 426,972 | 596,076 | 742,525 | 703,614 |
Cash | 631,908 | 1,087,720 | 929,026 | 950,052 |
Basic Shares | 562,000 | 578,000 | 589,000 | 593,000 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $2,263,576 | $2,354,554 | $2,237,215 | $2,289,463 |
Gross Profit | 2,263,576 | 2,354,554 | 2,237,215 | 2,289,463 |
EBITDA | 1,556,325 | 1,887,275 | 423,695 | 1,430,339 |
EBIT | 1,292,444 | 1,492,150 | 418,025 | 1,407,343 |
Net Income | 858,983 | 1,134,834 | 42,832 | 619,728 |
Net Change In Cash | 2,263,576 | 2,354,554 | 2,237,215 | 2,289,463 |
Cost of Revenue | 169,703 | 532,368 | ||
Free Cash Flow | 2,768,986 | 2,987,802 | 4,185,132 | 2,018,059 |
Cash | 929,026 | 477,010 | 1,710,751 | 1,541,048 |
Basic Shares | 594,000 | 602,900 | 437,972 | 414,802 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | $1.14 |
2025-03-31 | $1.06 |
2024-12-31 | $0.35 |
